Intersouth Partners

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

EDJX is developing a decentralized edge computing platform that aims to address the growing demand for efficient data processing. This ultra-low latency platform facilitates the rapid development of secure Internet of Things (IoT) and machine-to-machine (M2M) applications by executing serverless requests close to their source. The technology ensures that data is processed within an isolated environment at the nearest device, which helps mitigate latency and bandwidth challenges associated with traditional cloud computing. Additionally, EDJX offers services such as content delivery, object storage, and DNS, positioning itself as a leader in the landscape of edge computing solutions.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Azalea Health is a prominent provider of cloud-based healthcare solutions and services tailored for health systems, rural health clinics, billing companies, and community hospitals. The company offers a comprehensive suite of integrated technologies, including Electronic Health Records (EHR), Practice Management (PM), Revenue Cycle Management (RCM), telehealth services, and professional consulting. Azalea Health's solutions are designed to enhance patient engagement and streamline operational workflows for practices of various sizes and specialties. Additionally, the platform equips clients with tools to meet regulatory requirements such as Meaningful Use and ICD-10, ultimately aiming to optimize both operational efficiency and revenue generation.

6fusion is a company that offers an end-to-end cloud management platform designed to facilitate global workload distribution by transforming public and private cloud services into pay-per-use utilities. Utilizing its unique metering algorithm, the Workload Allocation Cube, 6fusion establishes a commercial standard for quantifying supply and demand for compute resources. The platform simplifies Infrastructure-as-a-Service for IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by providing a unified console that delivers insights into consumption, performance benchmarking, and cost allocation without imposing vendor lock-in. Additionally, the company employs financial intelligence analytics to standardize economic measurements for IT infrastructure operations and cloud services, enabling clients to assess utilization rates, consumption patterns, and cost efficiencies effectively.

LocationSmart is a leading provider of cloud-based location services, headquartered in Carlsbad, California. Founded in 1995, the company specializes in geolocation solutions for various industries, including gaming, IoT asset management, and transportation. Its services are designed to ensure geolocation compliance in sectors such as Daily Fantasy Sports, online poker, and online casinos. LocationSmart operates a comprehensive location platform that supports a wide range of connected devices and networks, enabling businesses to enhance customer engagement, operational efficiency, and security through real-time location data. The company's offerings include location determination based on IP addresses, cell or Wi-Fi IDs, and mobile app SDKs, along with messaging services for geo-enabled communication. With a focus on privacy and consent management, LocationSmart aims to protect user data while providing companies with actionable insights to optimize their operations. The company serves a diverse clientele, from startups to Fortune 500 companies, and has established itself as a significant player in the global location services market.

CallMiner, Inc. specializes in providing speech analytics solutions that help businesses analyze and extract insights from customer interactions, particularly within call centers. The company's flagship product, Eureka, employs artificial intelligence and natural language processing to transcribe and analyze conversations between agents and customers, enabling organizations to improve customer service, compliance monitoring, and overall business intelligence. CallMiner's offerings include myEureka, which automates performance management and provides feedback to contact center personnel, and Eureka Live, which monitors ongoing calls for specific language and acoustic characteristics. Additionally, it offers Eureka Essentials for smaller contact centers, along with a range of customer care, training, and advisory services. Founded in 2002 and headquartered in Waltham, Massachusetts, CallMiner also has offices in Fort Myers, Florida, and the United Kingdom, serving clients across various industries, including financial services, utilities, manufacturing, government, and hospitality.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, focused on developing innovative polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company specializes in creating in-situ forming foams designed to deliver local therapy for acute hemorrhage and other critical conditions such as vascular injury and repair. Arsenal Medical has developed two proprietary technology platforms: its therapeutic foam and AxioCore, a novel nanofiber technology that facilitates cell integration and tissue regeneration by enabling controlled delivery of biologics and therapeutics. The company utilizes safe, non-toxic, and biocompatible materials to enhance therapy in complex medical scenarios, positioning itself at the forefront of advancements in local treatment approaches.

Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, particularly targeting diabetic nephropathy. Founded in 2005 and headquartered in Research Triangle Park, North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to address complications associated with diabetes. This drug binds to a specific molecular target within the αVβ3 receptor, aiming to mitigate the harmful effects of hyperglycemia and improve patient outcomes. Vascular Pharmaceuticals operates at the intersection of biotechnology and healthcare, committed to innovative solutions for diabetes-related complications.

Azalea Health is a prominent provider of cloud-based healthcare solutions and services tailored for health systems, rural health clinics, billing companies, and community hospitals. The company offers a comprehensive suite of integrated technologies, including Electronic Health Records (EHR), Practice Management (PM), Revenue Cycle Management (RCM), telehealth services, and professional consulting. Azalea Health's solutions are designed to enhance patient engagement and streamline operational workflows for practices of various sizes and specialties. Additionally, the platform equips clients with tools to meet regulatory requirements such as Meaningful Use and ICD-10, ultimately aiming to optimize both operational efficiency and revenue generation.

Viamet Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies that target metalloenzymes, employing its proprietary Metallophile Technology. This technology leverages expertise in bioinorganic chemistry to identify and optimize small molecule compounds that inhibit validated metalloenzymes, which are crucial for various therapeutic applications. Viamet focuses on creating best-in-class treatments for serious conditions, including invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases, by enhancing the therapeutic potential of existing metalloenzyme inhibitors. Through its unique approach, Viamet aims to deliver novel, patentable therapeutic agents that effectively disrupt the cellular utilization of essential metal ions such as zinc and iron.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

Learn to play the music you love in the Zenph Online Education Network (ZOEN). We deliver the perfect match between teachers and students through live online music lessons. Whether you’re looking to learn your favorite song, seeking advice on perfecting your technique or searching for the right music teacher for your kids, taking a live online music lesson from one of the ZOEN’s experienced, nationally renowned music teachers is just a matter of a few clicks! The ZOEN is brought to you by Zenph, Inc. – our award winning Re-Performance® technology was named one of the “Best Ideas of the Year” by The New York Times Magazine and has earned us accolades from music lovers and critics the world over, including multiple GRAMMY® nominations. Based in North Carolina’s Research Triangle Park, we are a venture-backed technology company led by a team of music and software professionals with expertise in music education, consumer software, social gaming and entertainment.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, that specialized in the development of individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 1997 and formerly known as Merix Bioscience, the company utilized its proprietary Arcelis technology platform to create personalized treatments. Its notable product candidates included rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, aimed at treating human immunodeficiency virus in Phase II trials. Other investigational products included treatments for transplant rejection and autoimmune diseases. However, Argos Therapeutics filed for Chapter 7 bankruptcy and ceased operations on September 24, 2019.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software aimed at enhancing business performance through effective workforce measurement. Founded in 2001 and based in Charleston, South Carolina, the company provides tailored solutions for various industries, including technology, transportation, healthcare, government, biotech, and recreation. Its platform is designed to assist hourly hiring managers by streamlining the processes of sourcing, screening, and onboarding hourly workers, thereby improving efficiency and engagement. PeopleMatter's tools help service-industry brands optimize their recruitment efforts, ultimately contributing to improved customer satisfaction. In June 2016, the company was acquired by Snagajob, further expanding its reach and capabilities in the workforce management space.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, that specialized in the development of individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 1997 and formerly known as Merix Bioscience, the company utilized its proprietary Arcelis technology platform to create personalized treatments. Its notable product candidates included rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, aimed at treating human immunodeficiency virus in Phase II trials. Other investigational products included treatments for transplant rejection and autoimmune diseases. However, Argos Therapeutics filed for Chapter 7 bankruptcy and ceased operations on September 24, 2019.

Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software aimed at enhancing business performance through effective workforce measurement. Founded in 2001 and based in Charleston, South Carolina, the company provides tailored solutions for various industries, including technology, transportation, healthcare, government, biotech, and recreation. Its platform is designed to assist hourly hiring managers by streamlining the processes of sourcing, screening, and onboarding hourly workers, thereby improving efficiency and engagement. PeopleMatter's tools help service-industry brands optimize their recruitment efforts, ultimately contributing to improved customer satisfaction. In June 2016, the company was acquired by Snagajob, further expanding its reach and capabilities in the workforce management space.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

Zenoss Inc. is a developer of IT operations and application monitoring solutions, headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom. The company offers Zenoss Cloud, a software-as-a-service platform that normalizes machine data to prevent service disruptions across various IT environments. Its monitoring solutions provide comprehensive visibility into cloud, virtual, and physical infrastructures, assisting organizations in managing networks, servers, and storage. Zenoss aims to enhance IT service reliability by utilizing machine learning algorithms to predict and mitigate outages, thereby reducing downtime and operational costs. The company serves a range of industries, including federal, financial, and technology sectors, and has established strategic partnerships with notable firms such as Accenture, AWS, and Cisco. Zenoss was originally incorporated in 2005 as Zentinel, Inc.

Best ABT Molecular Imaging, Inc. is a medical imaging company specializing in the design, manufacture, marketing, and servicing of biomarker generator systems and related accessories. The company offers the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use, ensuring immediate availability and quality through comprehensive control tests for each dose generated. Founded by Ron and Lynda Nutt in 2006, Best ABT leverages its expertise in molecular imaging, which has roots dating back to the early 1980s. The company's innovative technology includes a self-shielded mini-cyclotron for producing the positron-emitting F-18 isotope and a microchemistry system for labeling specific molecules. Headquartered in Louisville, Tennessee, Best ABT distributes its products globally through a network of sales and service distributors, facilitating the expansion of PET imaging capabilities worldwide.

Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, particularly targeting diabetic nephropathy. Founded in 2005 and headquartered in Research Triangle Park, North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to address complications associated with diabetes. This drug binds to a specific molecular target within the αVβ3 receptor, aiming to mitigate the harmful effects of hyperglycemia and improve patient outcomes. Vascular Pharmaceuticals operates at the intersection of biotechnology and healthcare, committed to innovative solutions for diabetes-related complications.

Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.

Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, that specialized in the development of individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 1997 and formerly known as Merix Bioscience, the company utilized its proprietary Arcelis technology platform to create personalized treatments. Its notable product candidates included rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, aimed at treating human immunodeficiency virus in Phase II trials. Other investigational products included treatments for transplant rejection and autoimmune diseases. However, Argos Therapeutics filed for Chapter 7 bankruptcy and ceased operations on September 24, 2019.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Adaptivity is an IT solutions company founded in 2007 by experienced IT professionals focused on transforming the delivery of IT services. The company addresses the design challenges faced by enterprise IT by providing integrated services that optimize IT delivery across various computing environments. Adaptivity specializes in cloud computing, IT forensics, datacenter transformation, critical business application transformation, disaster recovery, and the implementation of virtual and dynamic infrastructure programs. With a commitment to leveraging real-time infrastructure and cloud utility models, Adaptivity aims to enhance business impact while enabling enterprises to optimize and redesign their systems in a dynamic and agile manner. The company's innovative approach has earned it recognition within the industry for its ability to streamline IT processes and improve organizational efficiency.

Semprius, Inc. is a company based in Durham, North Carolina, specializing in the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules. Founded in 2005, Semprius focuses on creating low-cost, high-performance solar solutions that are particularly effective in sunny and dry climates. The company's innovative micro-transfer printing technology allows for the production of highly efficient and reliable CPV modules, which are suitable for utility, commercial, industrial, and government applications. Additionally, Semprius licenses its micro-transfer printing technology for various non-solar applications, enabling the development of lightweight and thin products such as flat-panel displays, flexible electronics, and large-area sensors. This technology facilitates the integration of high-performance semiconductors across diverse platforms, enhancing the usability and accessibility of solar energy.

CSA Medical, Inc., established in 1993 and headquartered in Baltimore, Maryland, specializes in the development and manufacturing of spray cryotherapy medical devices. Its primary product, truFreeze, utilizes cold liquid nitrogen to destroy unwanted tissue across dermatology, gynecology, and general surgery fields while promoting healthy tissue regrowth. CSA Medical also offers the Rapid AV Spray Kit to enhance truFreeze's efficiency. The company operates a research and development facility in Lexington, Massachusetts.

simplifyMD is an electronic health records (EHR) provider based in Alpharetta, Georgia, established in 2006. The company offers a web-based platform designed for physician practices, enabling efficient management of electronic medical records. Its solutions include certified EHR systems, medical-grade document management, and Patient Health Record technologies. simplifyMD's products leverage barcode and optical character recognition to streamline the processing of documents, allowing medical offices to automate indexing and reduce the need for manual sorting of scans. This innovative approach aims to enhance the administrative efficiency of healthcare practices while ensuring compliance with industry standards.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Adaptivity is an IT solutions company founded in 2007 by experienced IT professionals focused on transforming the delivery of IT services. The company addresses the design challenges faced by enterprise IT by providing integrated services that optimize IT delivery across various computing environments. Adaptivity specializes in cloud computing, IT forensics, datacenter transformation, critical business application transformation, disaster recovery, and the implementation of virtual and dynamic infrastructure programs. With a commitment to leveraging real-time infrastructure and cloud utility models, Adaptivity aims to enhance business impact while enabling enterprises to optimize and redesign their systems in a dynamic and agile manner. The company's innovative approach has earned it recognition within the industry for its ability to streamline IT processes and improve organizational efficiency.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, focused on developing innovative polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company specializes in creating in-situ forming foams designed to deliver local therapy for acute hemorrhage and other critical conditions such as vascular injury and repair. Arsenal Medical has developed two proprietary technology platforms: its therapeutic foam and AxioCore, a novel nanofiber technology that facilitates cell integration and tissue regeneration by enabling controlled delivery of biologics and therapeutics. The company utilizes safe, non-toxic, and biocompatible materials to enhance therapy in complex medical scenarios, positioning itself at the forefront of advancements in local treatment approaches.

6fusion is a company that offers an end-to-end cloud management platform designed to facilitate global workload distribution by transforming public and private cloud services into pay-per-use utilities. Utilizing its unique metering algorithm, the Workload Allocation Cube, 6fusion establishes a commercial standard for quantifying supply and demand for compute resources. The platform simplifies Infrastructure-as-a-Service for IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by providing a unified console that delivers insights into consumption, performance benchmarking, and cost allocation without imposing vendor lock-in. Additionally, the company employs financial intelligence analytics to standardize economic measurements for IT infrastructure operations and cloud services, enabling clients to assess utilization rates, consumption patterns, and cost efficiencies effectively.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Semprius, Inc. is a company based in Durham, North Carolina, specializing in the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules. Founded in 2005, Semprius focuses on creating low-cost, high-performance solar solutions that are particularly effective in sunny and dry climates. The company's innovative micro-transfer printing technology allows for the production of highly efficient and reliable CPV modules, which are suitable for utility, commercial, industrial, and government applications. Additionally, Semprius licenses its micro-transfer printing technology for various non-solar applications, enabling the development of lightweight and thin products such as flat-panel displays, flexible electronics, and large-area sensors. This technology facilitates the integration of high-performance semiconductors across diverse platforms, enhancing the usability and accessibility of solar energy.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software aimed at enhancing business performance through effective workforce measurement. Founded in 2001 and based in Charleston, South Carolina, the company provides tailored solutions for various industries, including technology, transportation, healthcare, government, biotech, and recreation. Its platform is designed to assist hourly hiring managers by streamlining the processes of sourcing, screening, and onboarding hourly workers, thereby improving efficiency and engagement. PeopleMatter's tools help service-industry brands optimize their recruitment efforts, ultimately contributing to improved customer satisfaction. In June 2016, the company was acquired by Snagajob, further expanding its reach and capabilities in the workforce management space.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.

CallMiner, Inc. specializes in providing speech analytics solutions that help businesses analyze and extract insights from customer interactions, particularly within call centers. The company's flagship product, Eureka, employs artificial intelligence and natural language processing to transcribe and analyze conversations between agents and customers, enabling organizations to improve customer service, compliance monitoring, and overall business intelligence. CallMiner's offerings include myEureka, which automates performance management and provides feedback to contact center personnel, and Eureka Live, which monitors ongoing calls for specific language and acoustic characteristics. Additionally, it offers Eureka Essentials for smaller contact centers, along with a range of customer care, training, and advisory services. Founded in 2002 and headquartered in Waltham, Massachusetts, CallMiner also has offices in Fort Myers, Florida, and the United Kingdom, serving clients across various industries, including financial services, utilities, manufacturing, government, and hospitality.

Adaptivity is an IT solutions company founded in 2007 by experienced IT professionals focused on transforming the delivery of IT services. The company addresses the design challenges faced by enterprise IT by providing integrated services that optimize IT delivery across various computing environments. Adaptivity specializes in cloud computing, IT forensics, datacenter transformation, critical business application transformation, disaster recovery, and the implementation of virtual and dynamic infrastructure programs. With a commitment to leveraging real-time infrastructure and cloud utility models, Adaptivity aims to enhance business impact while enabling enterprises to optimize and redesign their systems in a dynamic and agile manner. The company's innovative approach has earned it recognition within the industry for its ability to streamline IT processes and improve organizational efficiency.

CallMiner, Inc. specializes in providing speech analytics solutions that help businesses analyze and extract insights from customer interactions, particularly within call centers. The company's flagship product, Eureka, employs artificial intelligence and natural language processing to transcribe and analyze conversations between agents and customers, enabling organizations to improve customer service, compliance monitoring, and overall business intelligence. CallMiner's offerings include myEureka, which automates performance management and provides feedback to contact center personnel, and Eureka Live, which monitors ongoing calls for specific language and acoustic characteristics. Additionally, it offers Eureka Essentials for smaller contact centers, along with a range of customer care, training, and advisory services. Founded in 2002 and headquartered in Waltham, Massachusetts, CallMiner also has offices in Fort Myers, Florida, and the United Kingdom, serving clients across various industries, including financial services, utilities, manufacturing, government, and hospitality.

6fusion is a company that offers an end-to-end cloud management platform designed to facilitate global workload distribution by transforming public and private cloud services into pay-per-use utilities. Utilizing its unique metering algorithm, the Workload Allocation Cube, 6fusion establishes a commercial standard for quantifying supply and demand for compute resources. The platform simplifies Infrastructure-as-a-Service for IT service providers, enterprises, independent software vendors, and infrastructure owners/operators by providing a unified console that delivers insights into consumption, performance benchmarking, and cost allocation without imposing vendor lock-in. Additionally, the company employs financial intelligence analytics to standardize economic measurements for IT infrastructure operations and cloud services, enabling clients to assess utilization rates, consumption patterns, and cost efficiencies effectively.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, focused on developing innovative polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company specializes in creating in-situ forming foams designed to deliver local therapy for acute hemorrhage and other critical conditions such as vascular injury and repair. Arsenal Medical has developed two proprietary technology platforms: its therapeutic foam and AxioCore, a novel nanofiber technology that facilitates cell integration and tissue regeneration by enabling controlled delivery of biologics and therapeutics. The company utilizes safe, non-toxic, and biocompatible materials to enhance therapy in complex medical scenarios, positioning itself at the forefront of advancements in local treatment approaches.

Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet edge and aggregation services tailored for carrier-class service providers. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional development offices in Westford, Massachusetts, and Bangalore, India, the company offers a diverse range of products. These include the Overture Orchestrator for cost-effective service delivery, Overture Analytics for actionable intelligence, and various Ethernet access devices that facilitate the transition from traditional TDM infrastructure to modern Ethernet networks. Key offerings also encompass the Overture 65vSE, a carrier-class server, and platforms like the Overture 6500 for performance-assured services across multiple transport mediums. By integrating packet-switched and circuit-switched technologies, Overture Networks delivers adaptable and cost-efficient solutions that cater to various service provider requirements.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software aimed at enhancing business performance through effective workforce measurement. Founded in 2001 and based in Charleston, South Carolina, the company provides tailored solutions for various industries, including technology, transportation, healthcare, government, biotech, and recreation. Its platform is designed to assist hourly hiring managers by streamlining the processes of sourcing, screening, and onboarding hourly workers, thereby improving efficiency and engagement. PeopleMatter's tools help service-industry brands optimize their recruitment efforts, ultimately contributing to improved customer satisfaction. In June 2016, the company was acquired by Snagajob, further expanding its reach and capabilities in the workforce management space.

Best ABT Molecular Imaging, Inc. is a medical imaging company specializing in the design, manufacture, marketing, and servicing of biomarker generator systems and related accessories. The company offers the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use, ensuring immediate availability and quality through comprehensive control tests for each dose generated. Founded by Ron and Lynda Nutt in 2006, Best ABT leverages its expertise in molecular imaging, which has roots dating back to the early 1980s. The company's innovative technology includes a self-shielded mini-cyclotron for producing the positron-emitting F-18 isotope and a microchemistry system for labeling specific molecules. Headquartered in Louisville, Tennessee, Best ABT distributes its products globally through a network of sales and service distributors, facilitating the expansion of PET imaging capabilities worldwide.

MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.

PeopleMatter, Inc. is a workforce management platform that specializes in talent management software aimed at enhancing business performance through effective workforce measurement. Founded in 2001 and based in Charleston, South Carolina, the company provides tailored solutions for various industries, including technology, transportation, healthcare, government, biotech, and recreation. Its platform is designed to assist hourly hiring managers by streamlining the processes of sourcing, screening, and onboarding hourly workers, thereby improving efficiency and engagement. PeopleMatter's tools help service-industry brands optimize their recruitment efforts, ultimately contributing to improved customer satisfaction. In June 2016, the company was acquired by Snagajob, further expanding its reach and capabilities in the workforce management space.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Acquired by Steinway & Sons Inc., January 2015. Zenph Sound Innovations is a developer of musical analysis technology focused on software services and apps related to music. Zenph Sound Innovations offers technology that converts audio recordings into datasets, enabling a virtual artist play re-performances, precisely replicating a musician’s playing in an original recording.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

Alimera Sciences, Inc. is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly targeting diseases affecting the retina. The company is best known for its product ILUVIEN, an intravitreal implant designed for the treatment of diabetic macular edema (DME), a serious condition that can lead to vision loss in individuals with diabetes. ILUVIEN is administered through a non-surgical procedure, delivering a continuous microdose of fluocinolone acetonide directly to the eye, thereby reducing the need for frequent injections. Alimera Sciences also collaborates with EyePoint Pharmaceuticals for the development of additional corticosteroid delivery technologies aimed at treating various eye conditions. The company markets its products through direct sales and distribution channels, serving physician offices, pharmacies, and hospitals. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia, and operates internationally, including in markets such as Germany, the United Kingdom, China, and the Middle East.

Viamet Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies that target metalloenzymes, employing its proprietary Metallophile Technology. This technology leverages expertise in bioinorganic chemistry to identify and optimize small molecule compounds that inhibit validated metalloenzymes, which are crucial for various therapeutic applications. Viamet focuses on creating best-in-class treatments for serious conditions, including invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases, by enhancing the therapeutic potential of existing metalloenzyme inhibitors. Through its unique approach, Viamet aims to deliver novel, patentable therapeutic agents that effectively disrupt the cellular utilization of essential metal ions such as zinc and iron.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

Semprius, Inc. is a company based in Durham, North Carolina, specializing in the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules. Founded in 2005, Semprius focuses on creating low-cost, high-performance solar solutions that are particularly effective in sunny and dry climates. The company's innovative micro-transfer printing technology allows for the production of highly efficient and reliable CPV modules, which are suitable for utility, commercial, industrial, and government applications. Additionally, Semprius licenses its micro-transfer printing technology for various non-solar applications, enabling the development of lightweight and thin products such as flat-panel displays, flexible electronics, and large-area sensors. This technology facilitates the integration of high-performance semiconductors across diverse platforms, enhancing the usability and accessibility of solar energy.

Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Bright View Technologies, Inc. is a prominent developer of microstructure-based optical films tailored for the global display industry. The company utilizes patented and proprietary technologies to create unique optical film products that exhibit superior performance characteristics suitable for various display technologies, including Plasma, LCD, Rear Projection, Front Projection, and OLED. In addition to display applications, Bright View's engineered optical devices also serve markets such as lighting and LiDAR, allowing clients to enhance brightness, efficiency, and uniformity in their products.

Ziptronix, Inc., established in 1998, specializes in designing, developing, and marketing advanced semiconductor integration technologies for the electronics industry. The company's core offerings include chip stacking solutions, enabling three-dimensional integrated circuits, and silicon substrate applications tailored for microelectromechanical systems (MEMS) and radio-frequency (RF) devices. Ziptronix' proprietary ZiBond and Direct Bond Interconnect technologies facilitate 3D bonding of silicon, enhancing signal path density and fostering innovation in electronics miniaturization.

Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.

Clarabridge is a Customer Experience Management platform that assists businesses in enhancing their customer interactions. By leveraging advanced text analytics and natural language processing technology, the platform transforms various forms of customer feedback—such as contact center calls, comments, and reviews—into actionable insights. This enables organizations to understand customer sentiments better and make informed decisions that drive improvements in customer experience. Since its establishment, Clarabridge has served numerous leading brands, helping them to grow sales, ensure compliance, and increase operational efficiency through a deep understanding of customer feedback.

Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

Athenix is a prominent company in the field of agricultural and industrial biotechnology, specializing in the development of innovative products, technologies, and processes for agricultural and chemical applications. The company has established a robust infrastructure dedicated to the discovery of new genes, which are then developed into practical solutions that address the needs of its customers. Athenix focuses on creating plants, microbes, and enzymes that provide resistance to insects and nematodes, as well as herbicide tolerance. Additionally, the company is involved in the discovery of genes and proteins that are applicable in the chemical and animal feed industries.

siXis is a semiconductor company that provides silicon circuit board technology.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, that specialized in the development of individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 1997 and formerly known as Merix Bioscience, the company utilized its proprietary Arcelis technology platform to create personalized treatments. Its notable product candidates included rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, aimed at treating human immunodeficiency virus in Phase II trials. Other investigational products included treatments for transplant rejection and autoimmune diseases. However, Argos Therapeutics filed for Chapter 7 bankruptcy and ceased operations on September 24, 2019.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates in clinical trials, with ALD-101 being the most advanced. Aldagen is currently conducting a pivotal Phase 3 clinical trial of ALD-101 to enhance umbilical cord blood transplants for treating inherited metabolic diseases in pediatric patients. Additionally, the company is involved in or supporting Phase 1 or Phase 1/2 clinical trials for three other product candidates: ALD-151 for improving cord blood transplants used in leukemia treatment; ALD-301 for critical limb ischemia; and ALD-201 for ischemic heart failure. Aldagen's work also includes developing therapies to address cardiovascular disease.

Alimera Sciences, Inc. is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly targeting diseases affecting the retina. The company is best known for its product ILUVIEN, an intravitreal implant designed for the treatment of diabetic macular edema (DME), a serious condition that can lead to vision loss in individuals with diabetes. ILUVIEN is administered through a non-surgical procedure, delivering a continuous microdose of fluocinolone acetonide directly to the eye, thereby reducing the need for frequent injections. Alimera Sciences also collaborates with EyePoint Pharmaceuticals for the development of additional corticosteroid delivery technologies aimed at treating various eye conditions. The company markets its products through direct sales and distribution channels, serving physician offices, pharmacies, and hospitals. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia, and operates internationally, including in markets such as Germany, the United Kingdom, China, and the Middle East.

Ziptronix, Inc., established in 1998, specializes in designing, developing, and marketing advanced semiconductor integration technologies for the electronics industry. The company's core offerings include chip stacking solutions, enabling three-dimensional integrated circuits, and silicon substrate applications tailored for microelectromechanical systems (MEMS) and radio-frequency (RF) devices. Ziptronix' proprietary ZiBond and Direct Bond Interconnect technologies facilitate 3D bonding of silicon, enhancing signal path density and fostering innovation in electronics miniaturization.

Mixx is a social news platform founded by Chris McGill, designed to enable users to discover and share news tailored to their interests and local context. Launched in 2007, it combines elements of social networking with news aggregation, allowing users to create personalized experiences akin to niche versions of other social news sites. The platform facilitates the submission, editing, and voting on stories, photos, and videos, thereby promoting content from both mainstream and niche publishers. Users receive customized home pages featuring relevant news items and have access to popular stories across various categories such as business, sports, and health. Additionally, Mixx encourages community engagement through topical groups, enhancing the curation of news submissions. The platform also released an API to allow web services to interact with its content, further integrating its offerings into the broader digital landscape.

Zenoss Inc. is a developer of IT operations and application monitoring solutions, headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom. The company offers Zenoss Cloud, a software-as-a-service platform that normalizes machine data to prevent service disruptions across various IT environments. Its monitoring solutions provide comprehensive visibility into cloud, virtual, and physical infrastructures, assisting organizations in managing networks, servers, and storage. Zenoss aims to enhance IT service reliability by utilizing machine learning algorithms to predict and mitigate outages, thereby reducing downtime and operational costs. The company serves a range of industries, including federal, financial, and technology sectors, and has established strategic partnerships with notable firms such as Accenture, AWS, and Cisco. Zenoss was originally incorporated in 2005 as Zentinel, Inc.

NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.

nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, focused on developing innovative polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company specializes in creating in-situ forming foams designed to deliver local therapy for acute hemorrhage and other critical conditions such as vascular injury and repair. Arsenal Medical has developed two proprietary technology platforms: its therapeutic foam and AxioCore, a novel nanofiber technology that facilitates cell integration and tissue regeneration by enabling controlled delivery of biologics and therapeutics. The company utilizes safe, non-toxic, and biocompatible materials to enhance therapy in complex medical scenarios, positioning itself at the forefront of advancements in local treatment approaches.

Overture Networks, Inc. specializes in providing virtualization solutions and high-speed carrier Ethernet edge and aggregation services tailored for carrier-class service providers. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional development offices in Westford, Massachusetts, and Bangalore, India, the company offers a diverse range of products. These include the Overture Orchestrator for cost-effective service delivery, Overture Analytics for actionable intelligence, and various Ethernet access devices that facilitate the transition from traditional TDM infrastructure to modern Ethernet networks. Key offerings also encompass the Overture 65vSE, a carrier-class server, and platforms like the Overture 6500 for performance-assured services across multiple transport mediums. By integrating packet-switched and circuit-switched technologies, Overture Networks delivers adaptable and cost-efficient solutions that cater to various service provider requirements.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Founded in 2001 and based in Waltham, Massachusetts, the company is known for its lead product candidate, vonapanitase, which is designed to improve hemodialysis vascular access outcomes. Vonapanitase, a recombinant human elastase, has successfully completed Phase II and Phase III clinical trials for patients suffering from chronic kidney disease and is currently being evaluated in a Phase I clinical trial for peripheral artery disease. The company aims to leverage its understanding of tissue remodeling to create effective treatments that address significant medical needs in these patient populations.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates in clinical trials, with ALD-101 being the most advanced. Aldagen is currently conducting a pivotal Phase 3 clinical trial of ALD-101 to enhance umbilical cord blood transplants for treating inherited metabolic diseases in pediatric patients. Additionally, the company is involved in or supporting Phase 1 or Phase 1/2 clinical trials for three other product candidates: ALD-151 for improving cord blood transplants used in leukemia treatment; ALD-301 for critical limb ischemia; and ALD-201 for ischemic heart failure. Aldagen's work also includes developing therapies to address cardiovascular disease.

Semprius, Inc. is a company based in Durham, North Carolina, specializing in the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules. Founded in 2005, Semprius focuses on creating low-cost, high-performance solar solutions that are particularly effective in sunny and dry climates. The company's innovative micro-transfer printing technology allows for the production of highly efficient and reliable CPV modules, which are suitable for utility, commercial, industrial, and government applications. Additionally, Semprius licenses its micro-transfer printing technology for various non-solar applications, enabling the development of lightweight and thin products such as flat-panel displays, flexible electronics, and large-area sensors. This technology facilitates the integration of high-performance semiconductors across diverse platforms, enhancing the usability and accessibility of solar energy.

Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.

Serenex is a U.S.-based medical drug discovery and development company established in 2000, specializing in oncology and related therapeutic areas. The company has developed a proprietary Hsp90 product platform, which includes a range of small molecule Hsp90 inhibitors targeting various conditions such as cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative disorders like Alzheimer's. Additionally, Serenex is advancing the development of SNX-1012, aimed at treating oral mucositis in patients with solid tumors. In 2008, Serenex was acquired by Pfizer, enhancing its capabilities in drug development and discovery.

Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.

Mixx is a social news platform founded by Chris McGill, designed to enable users to discover and share news tailored to their interests and local context. Launched in 2007, it combines elements of social networking with news aggregation, allowing users to create personalized experiences akin to niche versions of other social news sites. The platform facilitates the submission, editing, and voting on stories, photos, and videos, thereby promoting content from both mainstream and niche publishers. Users receive customized home pages featuring relevant news items and have access to popular stories across various categories such as business, sports, and health. Additionally, Mixx encourages community engagement through topical groups, enhancing the curation of news submissions. The platform also released an API to allow web services to interact with its content, further integrating its offerings into the broader digital landscape.

Viamet Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies that target metalloenzymes, employing its proprietary Metallophile Technology. This technology leverages expertise in bioinorganic chemistry to identify and optimize small molecule compounds that inhibit validated metalloenzymes, which are crucial for various therapeutic applications. Viamet focuses on creating best-in-class treatments for serious conditions, including invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases, by enhancing the therapeutic potential of existing metalloenzyme inhibitors. Through its unique approach, Viamet aims to deliver novel, patentable therapeutic agents that effectively disrupt the cellular utilization of essential metal ions such as zinc and iron.

Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.

FlatBurger, Inc. provides business infrastructure for supporting software developers working in hybrid software environments. It offers business infrastructure to complement the development tools employed in the Microsoft visual studio environment. The company focuses on serving the DotNetNuke community of software developers. FlatBurger, Inc. is based in Loudonville, New York with additional offices in northern Virginia and Troy.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

6th Sense Analytics provides software solutions for automated collection and analysis of software engineering process and product data. The company was founded in 2004 and is based in Morrisville, North Carolina. As of January 12, 2009, 6th Sense Analytics operates as a subsidiary of Rally Software Development Corp.

Clarabridge is a Customer Experience Management platform that assists businesses in enhancing their customer interactions. By leveraging advanced text analytics and natural language processing technology, the platform transforms various forms of customer feedback—such as contact center calls, comments, and reviews—into actionable insights. This enables organizations to understand customer sentiments better and make informed decisions that drive improvements in customer experience. Since its establishment, Clarabridge has served numerous leading brands, helping them to grow sales, ensure compliance, and increase operational efficiency through a deep understanding of customer feedback.

Ziptronix, Inc., established in 1998, specializes in designing, developing, and marketing advanced semiconductor integration technologies for the electronics industry. The company's core offerings include chip stacking solutions, enabling three-dimensional integrated circuits, and silicon substrate applications tailored for microelectromechanical systems (MEMS) and radio-frequency (RF) devices. Ziptronix' proprietary ZiBond and Direct Bond Interconnect technologies facilitate 3D bonding of silicon, enhancing signal path density and fostering innovation in electronics miniaturization.

Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates in clinical trials, with ALD-101 being the most advanced. Aldagen is currently conducting a pivotal Phase 3 clinical trial of ALD-101 to enhance umbilical cord blood transplants for treating inherited metabolic diseases in pediatric patients. Additionally, the company is involved in or supporting Phase 1 or Phase 1/2 clinical trials for three other product candidates: ALD-151 for improving cord blood transplants used in leukemia treatment; ALD-301 for critical limb ischemia; and ALD-201 for ischemic heart failure. Aldagen's work also includes developing therapies to address cardiovascular disease.

Jacket Micro Devices is a technology company based in Atlanta, Georgia, founded in 2004. It specializes in providing solutions for wireless modules, focusing on reducing the size and cost of radio frequency (RF) components used in various wireless devices. The company offers a range of products and services, including modules, design services, and substrates for integrated wireless products. Additionally, Jacket Micro Devices develops advanced technologies such as multi-layer organic (MLO) and low-temperature laminated organic (LTLO) solutions, which are essential for wireless system-in-package (SiP) designs.

nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

Zenoss Inc. is a developer of IT operations and application monitoring solutions, headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom. The company offers Zenoss Cloud, a software-as-a-service platform that normalizes machine data to prevent service disruptions across various IT environments. Its monitoring solutions provide comprehensive visibility into cloud, virtual, and physical infrastructures, assisting organizations in managing networks, servers, and storage. Zenoss aims to enhance IT service reliability by utilizing machine learning algorithms to predict and mitigate outages, thereby reducing downtime and operational costs. The company serves a range of industries, including federal, financial, and technology sectors, and has established strategic partnerships with notable firms such as Accenture, AWS, and Cisco. Zenoss was originally incorporated in 2005 as Zentinel, Inc.

Covega Corporation specializes in the development and production of optoelectronic components and subsystems, utilizing proprietary technologies in Indium Phosphide and Lithium Niobate. The company offers a range of high-performance optical devices and modules, including superluminescent diodes, semiconductor optical amplifiers, Fabry Perot lasers, gain chips, and lithium niobate modulators. With a significant portion of its revenue derived from the defense, medical, industrial, and instrumentation sectors, Covega has expanded beyond its initial focus on telecom, datacom, and CATV industries. The firm provides vertically integrated capabilities and foundry services, catering to a diverse clientele with tailored products and solutions designed to meet various operational needs.